http://www.igenericdrugs.com Review Rating: 100 out of 100 based on 929 reviews. 929 stars
Generic drugs
List of interchangeable brand and generic drugs
compare generic drug prices
 

Canesten Duo

Search a suitable generic or branded drugs, if you could not find the prescribed medicine. This site does not supply any medicines. It contains prices for information purposes only.
You should consult a doctor about the dosage before using this medicine!

DRUG NAME:     

 

Canesten Duo uses and description

Sort by popularity
Canesten Duo consists of Fluconazole, Hydrocortisone.

Fluconazole - Canesten Duo (Fluconazole) is an antifungal antibiotic.

Canesten Duo (Fluconazole) is used to treat infections caused by fungus, which can invade any part of the body including the mouth, throat, esophagus, lungs, bladder, genital area, and the blood.

Canesten Duo (Fluconazole) is also used to prevent fungal infection in people with weak immune systems caused by cancer treatment, bone marrow transplant, or diseases such as AIDS.

Canesten Duo (Fluconazole) may also be used for purposes not listed in this medication guide.

Pharmacology: Interferes with the formation of fungal cell membrane, causing leakage of cellular contents and cell death.

Indication: Oropharyngeal and esophageal candidiasis; vaginal candidiasis; prevention of candidiasis in bone marrow transplant; cryptococcal meningitis.

Canesten Duo (Fluconazole) is an antifungal drug from the group of triazole derivatives. Inhibits the synthesis of ergosterol disrupting the permeability of the cell wall. This medication is active against Candida, Microsporum, Cryptococcus neoformans, Trichophyton.

Canesten Duo (Fluconazole), a synthetic antifungal agent of the imidazole class, is used to treat vaginal candidiasis. It inhibits the fungal lanosterol 14 alpha-demethylase which thereby prevents the formation of ergosterol which is an essential component in the fungal cell membrane.

Indications:

  • Skin infections caused by fungi such as athlete\'s foot (tinea pedis), ringworm (tinea corporis), jock itch (tinea cruris), pityriasis versicolor,
  • Skin infections caused by candida albicans
  • Candida infection that affects mouth mucous lining (oral thrush), urinary tract, throat, lungs, bloodstream, heart.
  • Vaginal thrush(vaginits) caused by Candida albicans
  • Inflammation of the male genitals and/or foreskin (candidal balanitis).
  • Fungal infections caused by Cryptococcus fungi (cryptococcosis), including cryptococcal meningitis and infections affecting the lungs or skin.
  • Preventing fungal infections caused by fungi in patients with a weakened immunity and low white blood cell counts due to chemotherapy, radiotherapy or bone marrow transplants.
  • Prophylaxis of a disease caused by Cryptococcus fungi, eg cryptococcal meningitis, in patients with AIDS.

  • Canesten Duo (Fluconazole) is an antifungal medicine. It is used to prevent or treat fungal infections of the vagina, mouth, throat, digestive tract, lungs, brain, urinary tract, blood and other organs.

    Oral Superficial mucosal candidiasis

    Adult: (Except genital candidiasis) Usual dose: 50 mg daily, may increase to 100 mg daily if needed. Recommended treatment duration: 7-14 days (oropharyngeal candidiasis, except in severely immunocompromised patients), 14 days (atrophic oral candidiasis associated with dentures), 14-30 days (other mucosal candidiasis including oesophagitis).

    Child: >4 wk: Loading dose: 6 mg/kg followed by 3 mg/kg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Vaginal candidiasis

    Adult: 150 mg as a single dose. Oral Candidal balanitis

    Adult: 150 mg as a single dose. Oral Dermatophytosis

    Adult: 50 mg daily for up to 6 wk. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Pityriasis versicolor

    Adult: 50 mg daily for up to 6 wk. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Cutaneous candidiasis

    Adult: 50 mg daily for up to 6 wk. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Systemic candidiasis

    Adult: Initially, 400 mg followed by 200-400 mg daily. Max: 800 mg daily in severe infections. Treatment duration is based on clinical and mycological response but is usually at least 6-8 wk in cryptococcal meningitis. May also be given via IV infusion. To prevent relapse after a primary course of treatment for acute cryptococcal meningitis in AIDS patients: 100-200 mg daily, may also be given via IV admin.

    Child: >4 wk: 6-12 mg/kg daily; same doses may given every 72 hr in neonates up to 2 wk and every 48 hr in neonates 2-4 wk. Max: 400 mg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Cryptococcal infections

    Adult: Initially, 400 mg followed by 200-400 mg daily. Max: 800 mg daily in severe infections. Treatment duration is based on clinical and mycological response but is usually at least 6-8 wk in cryptococcal meningitis. May also be given via IV infusion. To prevent relapse after a primary course of treatment for acute cryptococcal meningitis in AIDS patients: 100-200 mg daily, may also be given via IV admin.

    Child: >4 wk: 6-12 mg/kg daily; same doses may given every 72 hr in neonates up to 2 wk and every 48 hr in neonates 2-4 wk. Max: 400 mg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Prophylaxis of fungal infections in immunocompromised patients

    Adult: 50-400 mg daily. May also be given via IV infusion.

    Child: 3-12 mg/kg daily; may also be given via IV infusion. For infants <2 wk, doses should be given every 72 hr; 2-4 wk, doses should be given every 48 hr. Max: 400 mg daily, or 12 mg/kg at recommended intervals in infants. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses.

    Oral Superficial mucosal candidiasis

    Adult: (Except genital candidiasis) Usual dose: 50 mg daily, may increase to 100 mg daily if needed. Recommended treatment duration: 7-14 days (oropharyngeal candidiasis, except in severely immunocompromised patients), 14 days (atrophic oral candidiasis associated with dentures), 14-30 days (other mucosal candidiasis including oesophagitis).

    Child: >4 wk: Loading dose: 6 mg/kg followed by 3 mg/kg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Vaginal candidiasis

    Adult: 150 mg as a single dose. Oral Candidal balanitis

    Adult: 150 mg as a single dose. Oral Dermatophytosis

    Adult: 50 mg daily for up to 6 wk. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Pityriasis versicolor

    Adult: 50 mg daily for up to 6 wk. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Cutaneous candidiasis

    Adult: 50 mg daily for up to 6 wk. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Systemic candidiasis

    Adult: Initially, 400 mg followed by 200-400 mg daily. Max: 800 mg daily in severe infections. Treatment duration is based on clinical and mycological response but is usually at least 6-8 wk in cryptococcal meningitis. May also be given via IV infusion. To prevent relapse after a primary course of treatment for acute cryptococcal meningitis in AIDS patients: 100-200 mg daily, may also be given via IV admin.

    Child: >4 wk: 6-12 mg/kg daily; same doses may given every 72 hr in neonates up to 2 wk and every 48 hr in neonates 2-4 wk. Max: 400 mg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Cryptococcal infections

    Adult: Initially, 400 mg followed by 200-400 mg daily. Max: 800 mg daily in severe infections. Treatment duration is based on clinical and mycological response but is usually at least 6-8 wk in cryptococcal meningitis. May also be given via IV infusion. To prevent relapse after a primary course of treatment for acute cryptococcal meningitis in AIDS patients: 100-200 mg daily, may also be given via IV admin.

    Child: >4 wk: 6-12 mg/kg daily; same doses may given every 72 hr in neonates up to 2 wk and every 48 hr in neonates 2-4 wk. Max: 400 mg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Prophylaxis of fungal infections in immunocompromised patients

    Adult: 50-400 mg daily. May also be given via IV infusion.

    Child: 3-12 mg/kg daily; may also be given via IV infusion. For infants <2 wk, doses should be given every 72 hr; 2-4 wk, doses should be given every 48 hr. Max: 400 mg daily, or 12 mg/kg at recommended intervals in infants. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Special Populations: Renal impairment: Initially, administer normal loading or initial doses followed by maintenance doses based on creatinine clearance. CrCl: >50 mL/min: ½ of the standard dose. Patients on regular haemodialysis should be given a standard dose of Canesten Duo (Fluconazole) every dialysis session.

    Oral Superficial mucosal candidiasis

    Adult: 50 mg daily increased to 100 mg daily. Recommended treatment duration: 7-14 days (oropharyngeal candidiasis), 14 days (atrophic oral candidiasis associated with dentures), 14-30 days (other mucosal candidal infections including oesophagitis).

    Child: >4 wk: Loading dose: 6 mg/kg followed by 3 mg/kg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Vaginal candidiasis

    Adult: 150 mg as a single dose. Oral Candidal balanitis

    Adult: 150 mg as a single dose. Oral Dermatophytosis, pityriasis versicolor and candida infections

    Adult: 50 mg daily for up to 6 wk. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Systemic candidasis

    Adult: Initially, 400 mg followed by 200-400 mg daily. Max: 800 mg daily in severe infections. Usual treatment duration: At least 6-8 wk in cryptococcal meningitis. May also be given via IV infusion.

    Child: >4 wk: 6-12 mg/kg daily; same doses may given every 72 hr in neonates up to 2 wk and every 48 hr in neonates 2-4 wk. Max: 400 mg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Cryptococcal infections including meningitis

    Adult: Initially, 400 mg followed by 200-400 mg daily. Max: 800 mg daily in severe infections. Usual treatment duration: At least 6-8 wk in cryptococcal meningitis. May also be given via IV infusion.

    Child: >4 wk: 6-12 mg/kg daily; same doses may given every 72 hr in neonates up to 2 wk and every 48 hr in neonates 2-4 wk. Max: 400 mg daily. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Prevention of relapse following a primary course of antifungal treatment for acute cryptococcal infections in patients with AIDS

    Adult: 100-200 mg daily. May also be given intravenously. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses. Oral Prophylaxis of fungal infections in immunocompromised patients

    Adult: 50-400 mg daily. May also be given via IV infusion.

    Child: 3-12 mg/kg daily; may also be given via IV infusion. For infants <2 wk, doses should be given every 72 hr; 2-4 wk, doses should be given every 48 hr. Max: 400 mg daily, or 12 mg/kg at recommended intervals in infants. Renal impairment: Normal initial doses; adjust subsequent doses based on CrCl. Patients on dialysis: Single recommended dose after each session. CrCl (ml/min) Dosage Recommendation <50 and not receiving dialysis Maintenance dose: 50% of the recommended doses.

    Indications:

    Adult: PO Superficial mucosal candidiasis 50 mg/day, up to 100 mg/day. Treatment duration: 7-30 days depending on condition. Candidal balanitis ; Vag candidiasis 150 mg as a single dose. Dermatophytosis; Pityriasis versicolor ; Cutaneous candidiasis 50 mg/day, for up to 6 wk. Systemic candidiasis; Cryptococcal infections Initial: 400 mg, then 200-400 mg/day. Max: 800 mg/day in severe cases. Prevention of relapse after a primary course of antifungal treatment for acute cryptococcal infections in AIDS patients 100-200 mg/day. Prophylaxis of fungal infections in immunocompromised patients 50-400 mg/day.

    Indications: Superficial mucosal candidiasis.

    Candidal balanitis, vaginal candidiasis.

    Dermatophytosis, pityriasis, versicolor and candida infections.

    Cryptococcal infections including meningitis, systemic candidasis.

    Prevention of relapse following a primary course of antifungal treatment for acute cryptococcal infections in patients with aids.

    Prophylaxis of fungal infections in immunocompromised patients.

    Hydrocortisone - Canesten Duo (Hydrocortisone) is in a class of drugs called steroids. Canesten Duo (Hydrocortisone) prevents the release of substances in the body that cause inflammation.

    Canesten Duo (Hydrocortisone) is used to treat many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.

    Canesten Duo (Hydrocortisone) may also be used for other purposes not listed in this medication guide.

    Pharmacology: Short-acting glucocorticoid that depresses formation, release, and activity of endogenous mediators of inflammation including prostaglandins, kinins, histamine, liposomal enzymes, and complement system. Also modifies body\'s immune response.

    Indication: Treatment of primary or secondary adrenal cortex insufficiency, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, allergic and inflammatory ophthalmic processes, respiratory diseases, hematologic disorders (idiopathic thrombocytopenic purpura), neoplastic diseases, edematous states (resulting from nephrotic syndrome), GI diseases (ulcerative colitis and sprue), multiple sclerosis, tuberculous meningitis, trichinosis with neurologic or myocardial involvement.

    Intra-articular or soft tissue administration

    Treatment of synovitis of osteoarthritis and symptoms of rheumatoid arthritis, bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, and post-traumatic osteoarthritis.

    Intralesional administration

    Treatment of keloids, lesions of lichen planus, psoriatic plaques, granuloma annulare, lichen simplex chronicus, discoid lupus erythematosus, necrobiosis lipoidica diabeticorum, alopecia areata, and cystic tumors of aponeurosis or tendon.

    Topical administration

    Treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, management of refractory lesions of psoriasis, and other deep-seated dermatoses; hygienic cleansing of irritated perianal and external vaginal areas.

    Rectal administration

    Relief of discomfort associated with hemorrhoids, perianal itching, or irritation.

    Glucocorticosteroid. Inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Inhibits the activity of phospholipase A2 which leads to suppression of the synthesis of prostaglandins and leukotrienes. Suppresses the release of COX (mainly COX-2), which also helps to reduce production of prostaglandins.

    Reduces the number of circulating lymphocytes (T-and B-cells), monocytes, eosinophils and basophils as a result of their displacement from the vascular bed to lymphoid tissue, suppresses the formation of antibodies.

    Canesten Duo (Hydrocortisone) suppresses the release of pituitary ACTH and beta-lipotropin but does not reduce the level of circulating beta-endorphin. Inhibits the secretion of TSH and FSH.

    With direct application of the receptacles has a vasoconstrictor effect.

    Canesten Duo (Hydrocortisone) has a pronounced dose-dependent effect on the metabolism of carbohydrates, proteins and fats. Stimulates gluconeogenesis, promotes the capture of amino acids by the liver and kidneys and increases the activity of enzymes of gluconeogenesis. In the liver of Canesten Duo (Hydrocortisone) increases glycogen deposition by stimulating the activity of glycogen synthase and synthesis of glucose from the products of protein metabolism. Increased blood glucose activates the secretion of insulin.

    Canesten Duo (Hydrocortisone) suppresses the seizure of glucose by fat cells that leads to activation of lipolysis. However, due to increased secretion of insulin is stimulation of lipogenesis which leads to the accumulation of fat.

    This medication has catabolic effect in lymphoid and connective tissue, muscle, adipose tissue, skin, bone tissue; to a lesser extent than the mineralocorticoid affects the processes of water and electrolyte metabolism: promotes the excretion of potassium ions and calcium, delay in the body of sodium and water. Osteoporosis and Itsenko-Cushing\'s syndrome are the main factors limiting the long-term therapy of GCS. As a result of catabolic actions may suppress growth in children.

    In high doses Canesten Duo (Hydrocortisone) may increase the excitability of brain tissue and contributes to lowering the threshold of convulsive readiness. It stimulates the excessive production of hydrochloric acid and pepsin in the stomach that promotes the development of peptic ulcers.

    For systems use therapeutic activity of Canesten Duo (Hydrocortisone) caused by anti-inflammatory, anti-allergic, immunosuppressive and antiproliferative action. When external and local application the therapeutic activity of Canesten Duo (Hydrocortisone) is due to anti-inflammatory, anti-allergic and antiexudative (due to vasoconstrictor effect) action. For anti-inflammatory activity this medicine is 4 times weaker than prednisolone, at mineralocorticoid activity is superior to other GCS.

    Canesten Duo (Hydrocortisone) is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical Canesten Duo (Hydrocortisone) is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

    Canesten Duo (Hydrocortisone) is a topical steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.

    Canesten Duo (Hydrocortisone) topical is used to treat inflammation of the skin caused by a number of conditions such as allergic reactions, eczema, or psoriasis.

    Canesten Duo (Hydrocortisone) is similar to a hormone produced naturally by your body. Canesten Duo (Hydrocortisone) is used as hormone replacement therapy to replace this natural hormone. Canesten Duo (Hydrocortisone) is also used to relieve skin inflammation, allergic reactions and to treat some types of rheumatism, asthma, eye, intestinal or blood disorders. Canesten Duo (Hydrocortisone) may also be used to treat other conditions as decided by your doctor. Canesten Duo (Hydrocortisone) belongs to a group of medicines called steroids.

    Oral Replacement therapy in adrenocortical insufficiency

    Adult: 20-30 mg daily in 2 divided doses.

    Child: 400-800 mcg/kg/day, in 2-3 divided doses. Intravenous As supplement in adrenal insufficiency during minor surgery under general anaesthesia

    Adult: In patients taking >10 mg of prednisolone or its equivalent by mouth daily. 25-50 mg at induction. Resume with usual oral corticosteroid after surgery. Intravenous As supplement in adrenal insufficiency during moderate or major surgery

    Adult: In patients taking >10 mg of prednisolone or its equivalent by mouth daily. Usual oral corticosteroid dose on the morning of the surgery followed by 25-50 mg at induction, then similar doses of Canesten Duo (Hydrocortisone) tid for 24 hr after moderate surgery or 48-72 hr after major surgery. Resume oral therapy once injections are stopped. Intravenous Acute adrenocortical insufficiency

    Adult: 100-500 mg 3-4 times/24 hr according to the severity of the condition and patient response. Fluids and electrolytes should be administered as needed to correct any metabolic disorder. Doses may also be given via IM inj but the response may be slower.

    Child: <1 yr: 25 mg; 1-5 yr: 50 mg; 6-12 yr: 100 mg. Fluids and electrolytes should be administered as needed to correct any metabolic disorder. Doses may also be given via IM inj but the response may be slower. Injection Soft tissue inflammation

    Adult: As Na phosphate or Na succinate esters: 100-200 mg as local inj. Intra-articular Joint inflammations

    Adult: As acetate: 5-50 mg depending on size of affected joint. Topical/Cutaneous Corticosteroid-responsive dermatoses

    Adult: Apply a 0.1-2.5% cream/ointment/lotion onto affected area.

    Canesten Duo (Hydrocortisone) helps to relieve itch and minor skin irritations. It can also relieve symptoms caused by dermatitis, eczema and psoriasis. Canesten Duo (Hydrocortisone) belongs to a group of medicines called steroids.

    Indications:

    Adult: PO Adrenocortical insufficiency 20-30 mg/day in 2 divided doses. IV Supplement in adrenal insufficiency during surgery under general anesth Patients taking >10 mg/day prednisolone or its equivalent by mouth: 25-50 mg at induction. Minor surgery: Resume usual oral dose after surgery; Moderate and major surgery: Administer usual oral corticosteroid dose on the morning of the surgery, then IV induction dose,continue w/ similar IV doses 3 times/day for 24 hr after moderate surgery or 48-72 hr after major surgery; resume usual oral dose after inj are stopped. Acute adrenocortical insufficiency 100-500 mg 3-4 times/24 hr depending on severity and response. Inj Soft-tissue inflammation As Na phosphate or Na succinate esters: 100-200 mg as local inj. Topical Corticosteroid-responsive dermatoses As 0.1-2.5% oint/cream/lotion: Apply as directed. Intra-articular Joint inflammations As acetate: 5-50 mg depending on size of affected joint.

    Oral Replacement therapy in adrenocortical insufficiency

    Adult: 20-30 mg daily in 2 divided doses.

    Child: 400-800 mcg/kg/day, in 2-3 divided doses. Intravenous As supplement in adrenal insufficiency during minor surgery under general anesth

    Adult: In patients taking >10 mg of prednisolone or its equivalent by mouth daily. 25-50 mg at induction. Resume with usual oral corticosteroid after surgery. Intravenous As supplement in adrenal insufficiency during moderate or major surgery

    Adult: In patients taking >10 mg of prednisolone or its equivalent by mouth daily. Usual oral corticosteroid dose on the morning of the surgery followed by 25-50 mg at induction, then similar doses of Canesten Duo (Hydrocortisone) tid for 24 hr after moderate surgery or 48-72 hr after major surgery. Resume oral therapy once injections are stopped. Intravenous Emergency treatment for acute adrenocortical insufficiency caused by addisonian or post-adrenaloctomy crisis, abrupt withdrawal of corticosteroid therapy, adrenal insufficiency, anaphylaxis, acute severe asthma, shock

    Adult: 100-500 mg 3-4 times/24 hr according to the severity of the condition and patient response.

    Child: 6-12 yr: 100 mg; 1-5 yr: 50 mg; <1 yr: 25 mg. Topical/Cutaneous Skin disorders

    Adult: Apply a 0.1-2.5% cream/ointment/lotion onto affected area. Intra-articular Joint inflammations

    Adult: As acetate: 5-50 mg depending on size of affected joint. Injection Soft tissue inflammation

    Adult: As Na phosphate or Na succinate esters: 100-200 mg as local inj.

    Canesten Duo (Hydrocortisone) Pharmafair is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Pharmafair inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Pharmetics is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Pharmetics inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) USL Pharmaceuticals is a glucocorticosteroid. Canesten Duo (Hydrocortisone) USL Pharmaceuticals inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Boots is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Boots inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Anabolic Laboratories is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Anabolic Laboratories inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Panray is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Panray inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Whiteworth Town is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Whiteworth Town inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Everylife is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Everylife inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Quad Pharmaceuticals is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Quad Pharmaceuticals inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Farmak is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Farmak inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Ferrante is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Ferrante inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Lannett is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Lannett inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Alpharma is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Alpharma inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Novopharm is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Novopharm inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Tatchempharmpreparaty is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Tatchempharmpreparaty inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Ambix Laboratories is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Ambix Laboratories inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) Stiefel Laboratories is a glucocorticosteroid. Canesten Duo (Hydrocortisone) Stiefel Laboratories inhibits the function of leukocytes and tissue macrophages. The migration of leukocytes in the area of inflammation. Impair the capacity of macrophages to phagocytosis and the formation of interleukin-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the field of inflammation. Decreases capillary permeability due to histamine release. Inhibits activity of fibroblasts and collagen formation.

    Canesten Duo (Hydrocortisone) has a pronounced dose-dependent effect on the metabolism of carbohydrates, proteins and fats. Stimulates gluconeogenesis, promotes the capture of amino acids by the liver and kidneys and increases the activity of enzymes of gluconeogenesis. In the liver of Canesten Duo (Hydrocortisone) increases glycogen deposition by stimulating the activity of glycogen

    Indications: Replacement therapy: Adrenal insufficiency.

    Adrenogenital syndrome.

    Nonendocrine diseases: Rheumatoid arthirits.

    Osteoarthritis, Acute gouty arthirits.

    Collagen diseases e.

    g.

    systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, nephritic syndrome, glomerulonephritis and related diseases.

    Severe allergic reactions e.

    g.

    anaphylaxis, angioneurotic edema, urticaria and serum sickness and related diseases.

    Autoimmune diseases e.

    g.

    haemolytic anaemia, idiopathic thrombocytopenic purpura, active chronic hepatitis and related diseases.

    Other lung diseases e.

    g.

    pulmonary edema, accelerate lung maturation and surfactant production in the foetus and prevent respiratory distress syndrome at birth.

    Infective diseases e.

    g.

    severe forms of tuberculosis, severe lepra reaction, certain forms of bacterial meningitis and Pneumocystis carinii pneumonia with hypoxia in AIDS patients along with proper antibiotic c

    Active ingredients: Fluconazole/Hydrocortisone
    Unit description, dosagePrice, USD

    List of canesten duo brand and generic drugs

    Fluconazole/Hydrocortisone (Malta)
     
    Privacy Policy
    © 2003 - 2014 igenericdrugs.com All Rights Reserved
     
    Disclamer